In our recent work (Baxevanis et al, 2002), by applying a CTL induction protocol using patients' dendritic cells (DC) pulsed with total peptide extracts from autologous HER-2/neu+ tumours, we could also demonstrate an immunodominance of HER-2(9369) in the tumour-specific CTL repertoire of the patients. This evidence concerns the gene ERBB2 and neoplasm.